Supplies of high-demand obesity treatments are improving, but that doesn’t mean they’re easier to get. Many employers and health insurers are scaling back coverage of Wegovy or Zepbound and a key government program, Medicare, doesn’t cover the drugs for obesity. Clouding the picture even further, some big employers are adding coverage. But their commitment isn’t…… MORE
